Eli Lilly (LLY)

1,098.57
-13.43 (-1.21%)
NYSE· Last Trade: Jun 20th, 5:03 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close1,112.00
Open1,120.49
Bid1,098.99
Ask1,103.99
Day's Range1,088.65 - 1,122.33
52 Week Range623.78 - 1,182.73
Volume4,470,563
Market Cap1.05T
PE Ratio (TTM)47.87
EPS (TTM)22.9
Dividend & Yield6.920 (0.63%)
1 Month Average Volume3,256,325

Chart

About Eli Lilly (LLY)

Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More

News & Press Releases

Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock?fool.com
Novo Nordisk has been telling investors that volume will eventually offset price cuts, and early results suggest investors should listen.
Via The Motley Fool · June 20, 2026
Lilly's 7 Acquisitions in 3 Months: Which Will Be the Biggest Game-Changer for the Pharma Giant?fool.com
Eli Lilly's spate of acquisitions is building out multiple areas of its pipeline at once.
Via The Motley Fool · June 20, 2026
3 Penny Stocks Under $5 Backed by Real Revenue Growthmarketbeat.com
These three penny stocks under $5 generate real revenue and have catalysts that analysts believe could drive significant upside
Via MarketBeat · June 20, 2026
Eli Lilly & Co (NYSE:LLY): A Dividend Growth Gem with Strong Fundamentalschartmill.com
Via Chartmill · June 19, 2026
Eli Lilly & Co. (NYSE:LLY): High Growth Momentum Meets Strong Technical Breakout Setupchartmill.com
Via Chartmill · June 16, 2026
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trendmarketbeat.com
With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.
Via MarketBeat · June 20, 2026
3 Reasons to Buy Eli Lilly Stockfool.com
Despite several setbacks over the past year, the drugmaker marches on.
Via The Motley Fool · June 20, 2026
Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up. Here's What That Means for Both Stocks.fool.com
These companies don't typically compete directly with one another, but that might change soon.
Via The Motley Fool · June 20, 2026
Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 15 Yearsbenzinga.com
Eli Lilly (NYSE:LLY) has outperformed the market over the past 15 years by 12.92% on an annualized basis producing an average annual ...
Via Benzinga · June 19, 2026
The Next Wave of Medical AI Could Mint More Millionaires Than the First -- Here Are the Stocks to Ownfool.com
AI's next winners in healthcare could be companies like Eli Lilly and Twist Bioscience.
Via The Motley Fool · June 19, 2026
Market-Weighted Healthcare or Active Manager Selection? IYH vs. PINKfool.com
The iShares U.S. Healthcare ETF (IYH) tracks a broad healthcare index, while the Simplify Health Care ETF (PINK) gives an active manager more room to choose. That difference matters for investors deciding whether they want benchmark exposure or a more concentrated healthcare portfolio.
Via The Motley Fool · June 18, 2026
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Boughtfool.com
After a few days of purging, the Ark Invest growth investor is buying stocks again.
Via The Motley Fool · June 18, 2026
3 Stocks Doing the Heavy Lifting in Healthcare’s Reboundmarketbeat.com
Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound.
Via MarketBeat · June 18, 2026
Vanguard (VHT) vs VanEck (PPH): Which Healthcare ETF Is the Better Buy?fool.com
Broader diversification or higher yield? Explore how these two healthcare ETFs stack up for different investor goals.
Via The Motley Fool · June 18, 2026
Is iShares Pharma ETF (IHE) or SPDR's Biotech ETF (XBI) the Better Long-Term Buy for Investors?fool.com
Compare risk profiles, sector concentration, and income potential as these two healthcare ETFs take different approaches to growth and stability.
Via The Motley Fool · June 17, 2026
3 Underrated Dividend Stocks That Could Generate Reliable Cash Flow for Your Portfolio for Decadesfool.com
These stocks may not be your first choices when looking for dividends, but they have been income-generating machines for years.
Via The Motley Fool · June 17, 2026
Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock?fool.com
These two healthcare leaders have a long history of competing against one another.
Via The Motley Fool · June 16, 2026
Health Care ETFs: XLV Delivers Low Fees and Solid Returnsfool.com
Explore how portfolio concentration and stock count set these healthcare ETFs apart, impacting risk and diversification for investors seeking sector exposure.
Via The Motley Fool · June 16, 2026
FHLC vs. IYH: Which Healthcare ETF Is the Better Buy in 2026?fool.com
Portfolio size and stock selection set these healthcare ETFs apart and help shape their risk and return profiles.
Via The Motley Fool · June 16, 2026
3 Under-the-Radar Stocks to Buy and Hold for a Decadefool.com
All three could become highly prominent biotech companies within 10 years.
Via The Motley Fool · June 16, 2026
1 Profitable Stock to Target This Week and 2 We Avoid
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
Via StockStory · June 16, 2026
Invesco's RSPH vs. PJP: Which Health Care ETF Is the Better Fund For The GLP-1 Revolution?fool.com
Compare portfolio strategies, cost structures, and risk profiles as two Invesco healthcare ETFs take different paths to sector exposure.
Via The Motley Fool · June 15, 2026
Should You Buy Eli Lilly Stock Now or Wait for a Dip?fool.com
Eli Lilly has experienced robust growth, but investors may be thinking twice about the stock due to its high valuation.
Via The Motley Fool · June 15, 2026
Eli Lilly Eyes Label Expansion For Leukemia Drugbenzinga.com
Eli Lilly's Phase 3 BRUIN CLL-322 study showed Jaypirca combination therapy cut progression or death risk by 45% in CLL/SLL.
Via Benzinga · June 15, 2026
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX)
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Royalty Pharma (N...
Via StockStory · June 14, 2026